A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective

• Egile Nagusiak: Baker CL (Egilea), Ding Y (Egilea), Ferrufino CP (Egilea), Kowal S (Egilea), Tan J (Egilea), Subedi P (Egilea)
• Formatua: Liburua
• Argitaratua: Dove Medical Press, 2018-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Christine L Baker,1 Yao Ding,2 Cheryl P Ferrufino,2 Stacey Kowal,2 Jenen Tan,3 Prasun Subedi1 1Patient & Health Impact, Pfizer, Inc, New York, NY, USA; 2Health Economics & Outcomes Research, Real World Evidence Solutions, IQVIA, Fairfax, VA, USA; 3IQVIA, San Francisco, CA, USA Introduction:...